TRANSLATIONAL VALIDATION OF GLUTAMINYL-CYCLASES AS PROMISING NEW TARGET FOR TREATMENT OF DKD

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/b10c6ca5ec10a4dea6641c0db7cb738a.pdf
TRANSLATIONAL VALIDATION OF GLUTAMINYL-CYCLASES AS PROMISING NEW TARGET FOR TREATMENT OF DKD

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Christine
Wenzkowski
Christine Wenzkowski christine.wenzkowski@vivoryon.com Vivoryon Therapeutics N.V. Halle (Saale) Germany *
Torsten Hoffmann torsten.hoffmann@vivoryon.com Vivoryon Therapeutics N.V. Halle (Saale) Germany -
Michael Schaeffer michael.schaeffer@vivoryon.com Vivoryon Therapeutics N.V. Halle (Saale) Germany -
Sylvia Schell-Mader Sylvia.Schell-Mader@vivoryon.com Vivoryon Therapeutics N.V. Halle (Saale) Germany -
Antje Meyer Antje.Meyer@vivoryon.com Vivoryon Therapeutics N.V. Halle (Saale) Germany -
Stefan Tasler Stefan.Tasler@vivoryon.com Vivoryon Therapeutics N.V. Halle (Saale) Germany -
Katharina Fuchs Katharina.Fuchs@vivoryon.com Vivoryon Therapeutics N.V. Halle (Saale) Germany -
Tanja Wassmann Tanja.Wassmann@vivoryon.com Vivoryon Therapeutics N.V. Halle (Saale) Germany -
Kevin J. Carroll kevin.carroll@kjcstatistics.ie KJC Statistics Ltd Dublin Ireland -
Frank Weber 199ftw@googlemail.com Vivoryon Therapeutics N.V. Halle (Saale) Germany -
Tobias B. Huber t.huber@uke.de Universitätsklinikum Hamburg-Eppendorf III. Department of Medicine Hamburg Germany -
-
-
-
-